Phase 2
18 Years
75 Years
18 Years
75 Years
Open (Enrolling)
Both
Feeling Anxious
Both
Feeling Anxious
Trial Information
Inclusion Criteria:
- Patients aged from 18 to 75 years
- Patient schedules for insertion of long-lasting intravenous device
Exclusion Criteria:
- History of previous insertion of long-lasting intravenous device or central
intravenous catheter
- long term treatment of gabapentin or pregabalin
- Hypersensitivity to pregabalin or any of the excipients
- Hypersensitivity to hydroxyzine, one of its metabolites, one of the excipients,
another derivative of piperazine, aminophylline or ethylene diamine.
- Patient at risk of glaucoma e
- Patient at risk for urinary retention
- Patient severe respiratory failure
- Patient at the general condition not too corrupted (ASA IV)
- Renal failure with creatinin clearance < 30 ml / min
- Patient not affiliated to Social Security
- Pregnant or lactating
- Patients in emergency situations
- Inpatient without consent
Type of Study:
Interventional
Study Design:
N/A
Outcome Measure:
Efficacy treatment
Outcome Description:
anxiety score VAS: 0 to 100
Principal Investigator
Bertrand DEBAENE, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Poitiers University Hospital
Authority:
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study ID:
GABAPAC
NCT ID:
NCT01675986
Start Date:
Completion Date:
Related Keywords:
- Feeling Anxious
Name | Location |
|---|
